The data is created automatically. Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data sh...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data should not be seen as a fulfillment...
COPENHAGEN, Denmark, October 31, 2024- Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Significant expansion
Evaxion plans to select a lead ERV precision vaccine candidate during the second half of 2025 COPENHAGEN, Denmark,December 12, 2024-Evaxion Biotech A/S(NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, obtains p...
The data is created automatically. Nasdaq Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, Nasdaq Iceland hf, Nasdaq Oslo ASA, Nasdaq Tallinn AS, Nasdaq Riga AS and AB Nasdaq Vilnius (“Nasdaq”) does not guarantee that the data is exhaustive, accurate or up to date. The data sh...